Carmustine STADA (100 mg)
Powder and solvent for concentrate for solution for infusion containing carmustine — cytotoxic alkylating agent
Quick Facts About Carmustine STADA
Key Takeaways About Carmustine STADA
- Specialist supervision required: Carmustine STADA is a potent cytotoxic agent that must only be administered by healthcare professionals experienced in cancer chemotherapy, in a hospital or specialized oncology setting
- Delayed bone marrow suppression: Unlike many other chemotherapy drugs, carmustine causes characteristically delayed myelosuppression with the lowest blood cell counts occurring 4 to 6 weeks after each dose – regular blood monitoring is essential
- Pulmonary toxicity risk: Carmustine can cause cumulative lung damage including pulmonary fibrosis, which may be irreversible – lung function must be assessed before and during treatment
- Crosses the blood-brain barrier: One of the few chemotherapy agents that effectively penetrates the central nervous system, making it particularly useful for treating brain tumors
- Contraindicated in pregnancy: Carmustine is teratogenic and must not be used during pregnancy – effective contraception is required for both male and female patients during and after treatment
What Is Carmustine STADA and What Is It Used For?
Carmustine STADA is a cytotoxic chemotherapy medication containing the active substance carmustine (also known as BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea). It belongs to the nitrosourea subclass of alkylating agents and is used to treat brain tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.
Carmustine is one of the most established alkylating agents in oncology, having been used in clinical practice since the 1960s. It exerts its anticancer effect by alkylating and cross-linking DNA, thereby disrupting the replication and transcription of genetic material in rapidly dividing cancer cells. The drug is a bifunctional alkylating agent, meaning it can form bonds with two different sites on the DNA molecule simultaneously, creating interstrand cross-links that are particularly difficult for cancer cells to repair.
A key clinical advantage of carmustine is its high lipophilicity, which allows it to cross the blood-brain barrier effectively. This property makes it one of the few systemic chemotherapy agents that can achieve therapeutic concentrations within the central nervous system. For this reason, carmustine has historically been a cornerstone of treatment for malignant brain tumors, including glioblastoma multiforme, the most aggressive and common primary brain tumor in adults. In the treatment of glioblastoma, carmustine may be used as part of multi-agent chemotherapy regimens or as a single agent.
Beyond brain tumors, carmustine is an important component of combination chemotherapy protocols for haematological malignancies. In Hodgkin lymphoma, it is used as part of the BEAM regimen (carmustine, etoposide, cytarabine, and melphalan), which is the standard conditioning regimen prior to autologous stem cell transplantation for relapsed or refractory disease. In multiple myeloma, carmustine-containing regimens have been used both as induction therapy and as part of high-dose conditioning before stem cell transplant.
The approved indications for Carmustine STADA include the treatment of brain tumors such as glioblastoma multiforme, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. It is also indicated for Hodgkin disease (Hodgkin lymphoma) and non-Hodgkin lymphomas as a single agent or in established combination regimens, and for multiple myeloma in combination with prednisone or as part of other multi-drug protocols. Additionally, carmustine may be used in gastrointestinal tumors and malignant melanoma in selected clinical situations.
Carmustine STADA is a cytotoxic medication that must only be prepared and administered by qualified healthcare professionals in a hospital or specialised oncology clinic. It is given as a slow intravenous infusion over 1 to 2 hours. Patients do not handle or administer this medication themselves. All preparation must follow institutional cytotoxic handling guidelines to protect both patients and healthcare workers.
What Should You Know Before Receiving Carmustine STADA?
Before starting treatment with Carmustine STADA, your oncologist will perform comprehensive assessments including complete blood counts, liver function tests, kidney function tests, and pulmonary function tests. Several important contraindications and precautions must be considered before carmustine can be safely administered.
Contraindications
Carmustine STADA must not be used in patients who have a known hypersensitivity to carmustine or to any of the excipients in the formulation. It is contraindicated in patients with severe, pre-existing bone marrow depression, whether caused by previous chemotherapy, radiation therapy, or other medical conditions. The degree of myelosuppression must be carefully assessed before each treatment cycle, as cumulative bone marrow toxicity is one of the most serious risks associated with nitrosourea therapy.
Carmustine is contraindicated during pregnancy and breastfeeding due to its teratogenic and embryotoxic properties. Women who are pregnant or suspect they may be pregnant must not receive carmustine. Additionally, carmustine should not be administered concurrently with live vaccines, as the immunosuppressive effects of the drug may lead to uncontrolled infection from the vaccine organism. Patients should also avoid contact with individuals who have recently received live vaccines.
Patients with severe hepatic impairment or severe renal impairment may not be suitable candidates for carmustine therapy, as these conditions can significantly alter the drug's pharmacokinetics and increase the risk of toxicity. Your oncologist will evaluate your organ function before determining whether carmustine is appropriate and, if so, what dose adjustments may be necessary.
Warnings and Precautions
Carmustine carries several serious warnings that must be understood by both healthcare providers and patients before treatment begins. The following precautions are essential for safe use of this medication:
- Bone marrow suppression: Carmustine causes delayed and cumulative myelosuppression. Thrombocytopenia (low platelets) typically reaches its nadir at 4 to 5 weeks after a dose, and leukopenia (low white blood cells) at 5 to 6 weeks. Complete blood counts must be performed weekly for at least 6 weeks after each dose. Subsequent doses should not be given until blood counts have recovered to acceptable levels.
- Pulmonary toxicity: Carmustine can cause dose-related pulmonary fibrosis that may be irreversible and potentially fatal. The risk increases with cumulative doses exceeding 1,400 mg/m², but pulmonary toxicity can occur at lower cumulative doses. Baseline and periodic pulmonary function tests (including diffusion capacity for carbon monoxide, DLCO) are mandatory. Treatment must be discontinued if significant pulmonary deterioration is detected.
- Hepatotoxicity: Reversible elevations in liver enzymes (transaminases, alkaline phosphatase, bilirubin) can occur. Liver function should be monitored before and during treatment. Carmustine should be used with caution in patients with pre-existing liver disease.
- Nephrotoxicity: Carmustine can cause progressive renal impairment, including decreased kidney size and azotaemia, particularly at high cumulative doses or with prolonged treatment. Kidney function should be monitored regularly.
- Secondary malignancies: As with other alkylating agents, carmustine is associated with an increased risk of developing secondary cancers, including acute leukaemia and myelodysplastic syndromes, particularly after prolonged treatment.
- Infusion-site reactions: Carmustine can cause severe local tissue damage if it extravasates (leaks from the vein into surrounding tissue). The infusion site must be monitored carefully throughout administration. Pain, burning, or swelling at the infusion site should prompt immediate cessation of the infusion.
Due to the severity of potential toxicities, blood counts, liver function, kidney function, and pulmonary function must all be monitored at baseline and at regular intervals throughout treatment. Your oncologist will schedule these tests and evaluate the results before each treatment cycle. Any significant deterioration in organ function may necessitate dose reduction, treatment delay, or discontinuation of carmustine therapy.
Pregnancy and Breastfeeding
Carmustine STADA is strictly contraindicated during pregnancy. Animal studies have demonstrated teratogenic and embryotoxic effects, and based on its mechanism of action as a DNA-alkylating agent, carmustine is expected to cause significant harm to a developing fetus. There is a risk of congenital malformations, growth restriction, and fetal death. Women of childbearing potential must have a negative pregnancy test before starting treatment and must use highly effective contraception during treatment and for at least 6 months after the last dose of carmustine.
Male patients being treated with carmustine must also use effective contraception during treatment and for at least 3 months after the last dose, as carmustine may cause genetic damage to sperm cells. Men should be counselled about the possibility of permanent infertility following treatment, and sperm banking should be discussed prior to initiating therapy.
Breastfeeding must be discontinued during treatment with carmustine and should not be resumed after treatment is completed. It is not known whether carmustine or its metabolites are excreted in human breast milk, but given the drug's cytotoxic nature and potential for serious adverse effects in nursing infants, breastfeeding is contraindicated.
Carmustine may cause permanent infertility in both men and women. Patients of reproductive age should be counselled about fertility preservation options (such as sperm banking or oocyte cryopreservation) before starting treatment. Effective contraception is mandatory during treatment and for a defined period after the last dose. If pregnancy occurs during treatment, inform your oncologist immediately.
How Does Carmustine STADA Interact with Other Drugs?
Carmustine can interact with several other medications, potentially increasing the risk of toxicity or reducing therapeutic efficacy. The most clinically significant interactions involve other myelosuppressive agents, certain anticonvulsants, and live vaccines. Your oncology team will carefully review all concurrent medications before initiating treatment.
Drug interactions with carmustine can be categorised into pharmacokinetic interactions (where another drug affects how carmustine is metabolised or eliminated) and pharmacodynamic interactions (where combined effects of drugs increase toxicity or reduce efficacy). Because carmustine is primarily metabolised in the liver through non-enzymatic decomposition and partly through hepatic microsomal enzymes, drugs that affect liver function or hepatic enzyme activity can potentially alter carmustine exposure.
One of the most important considerations is the additive myelosuppressive effect when carmustine is combined with other chemotherapy agents, radiation therapy, or any medication that suppresses bone marrow function. Since carmustine already causes severe and delayed bone marrow suppression, the addition of other myelotoxic agents requires careful dose planning and intensified blood count monitoring. This is managed by the oncology team as part of protocol-based combination chemotherapy regimens.
Carmustine has been reported to reduce the plasma levels of phenytoin when the two drugs are used concurrently. This is clinically relevant because many patients with brain tumors receive anticonvulsant therapy to prevent seizures. If seizure control deteriorates during carmustine treatment, phenytoin levels should be measured and the dose adjusted accordingly. Your neurologist and oncologist should coordinate to manage anticonvulsant therapy during chemotherapy.
Known Drug Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Phenytoin | Pharmacokinetic | Carmustine reduces phenytoin plasma levels, risking seizure breakthrough | Monitor phenytoin levels; adjust dose as needed |
| Cimetidine | Pharmacokinetic | Cimetidine may enhance carmustine myelotoxicity by inhibiting its metabolism | Avoid concurrent use; use alternative H2-blocker or PPI |
| Other myelosuppressive agents | Pharmacodynamic | Additive bone marrow suppression with increased risk of severe cytopenias | Monitor blood counts more frequently; adjust doses per protocol |
| Live vaccines (e.g., MMR, varicella) | Immunological | Risk of disseminated vaccine-strain infection due to immunosuppression | Contraindicated; avoid live vaccines during and after treatment |
| Digoxin | Pharmacokinetic | Carmustine may reduce digoxin absorption and plasma levels | Monitor digoxin levels; adjust dose if necessary |
| Melphalan | Pharmacodynamic | Increased pulmonary toxicity when combined (e.g., BEAM regimen) | Monitor pulmonary function closely; use only in established protocols |
| Corticosteroids (dexamethasone) | Supportive | Commonly co-administered to reduce cerebral oedema; no adverse interaction | Standard co-administration is appropriate for brain tumor patients |
The table above is not exhaustive. Your oncology team maintains a complete record of all your medications and will assess potential interactions before each treatment cycle. Always inform your oncologist, pharmacist, and other healthcare providers about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. Some herbal products (such as St. John's Wort) can interact with chemotherapy agents in unpredictable ways.
Patients receiving carmustine chemotherapy should avoid alcohol consumption. Alcohol can increase the risk of hepatotoxicity and may worsen nausea and other gastrointestinal side effects associated with chemotherapy. Additionally, alcohol can impair immune function, which is already compromised by carmustine's myelosuppressive effects. Discuss any questions about alcohol with your oncology team.
What Is the Correct Dosage of Carmustine STADA?
The standard dosage of Carmustine STADA is 150 to 200 mg/m² body surface area, administered as a single intravenous infusion or divided over two consecutive days, every 6 weeks. The dose is always calculated by your oncologist based on your body surface area, blood counts, and organ function. Carmustine is never self-administered.
Carmustine dosing is highly individualised and depends on several factors, including the type and stage of cancer being treated, the patient's body surface area, haematological status, renal and hepatic function, previous treatment history, and whether carmustine is being used as a single agent or as part of a combination chemotherapy protocol. The characteristically delayed myelosuppression caused by carmustine means that treatment cycles are typically spaced at least 6 weeks apart to allow bone marrow recovery.
Adults – Standard Dosing
Single-Agent Therapy
When used as a single agent, the recommended dose of carmustine is 150 to 200 mg/m² of body surface area, given as a single intravenous infusion or divided into two equal daily doses on two consecutive days (e.g., 75 to 100 mg/m² on day 1 and day 2). This cycle is repeated every 6 weeks, provided that blood counts have returned to acceptable levels. The typical criteria for re-treatment require platelets above 100,000/µL and white blood cells above 4,000/µL.
For previously treated patients or those with compromised bone marrow reserve, the initial dose should be reduced to 100 to 130 mg/m². Subsequent doses must be adjusted based on the nadir blood counts from the previous cycle. If the platelet nadir was 25,000 to 74,999/µL or the leukocyte nadir was 2,000 to 2,999/µL, the next dose should be reduced by 30%. If the platelet nadir was below 25,000/µL or the leukocyte nadir below 2,000/µL, the next dose should be reduced by 50%.
Combination Chemotherapy (BEAM Regimen)
In the BEAM conditioning regimen for autologous stem cell transplantation (used in Hodgkin lymphoma and non-Hodgkin lymphoma), carmustine is typically given at a dose of 300 mg/m² as a single intravenous infusion on day −6 (six days before stem cell infusion). This high-dose regimen is only administered in specialised transplant centres with appropriate supportive care, including access to stem cell rescue. The BEAM regimen also includes etoposide (200 mg/m² on days −5 to −2), cytarabine (200 mg/m² twice daily on days −5 to −2), and melphalan (140 mg/m² on day −1).
Children and Adolescents
Paediatric Use
The safety and efficacy of carmustine in children have not been established through large-scale controlled clinical trials. When carmustine is used in paediatric patients (e.g., for certain brain tumors such as medulloblastoma or brainstem glioma), dosing is determined by the treating paediatric oncologist based on the specific treatment protocol, the child's body surface area, and individual clinical assessment. Paediatric dosing typically follows the same mg/m² principles as adult dosing but may be adjusted for the developing child's organ function and tolerance. Close monitoring is essential, as children may be more susceptible to certain toxicities, including delayed effects on growth and neurocognitive development.
Elderly Patients
Geriatric Dosage Considerations
Elderly patients may have reduced bone marrow reserve and diminished hepatic and renal function, increasing the risk of toxicity from carmustine. The initial dose should be at the lower end of the recommended range, and dose adjustments should be made based on careful assessment of organ function and haematological tolerance. Elderly patients are also at greater risk of pulmonary toxicity and should have thorough baseline pulmonary function testing. More frequent monitoring of blood counts, liver function, kidney function, and pulmonary function is recommended in this population.
Missed Dose
Since carmustine is administered in a hospital setting by healthcare professionals according to a scheduled treatment protocol, missed doses in the traditional sense do not apply. However, treatment cycles may be delayed if blood counts have not recovered sufficiently or if there is evidence of organ toxicity. Your oncologist will determine the appropriate timing for each treatment cycle based on your clinical status and laboratory results. A delay of one or more weeks is common and does not usually compromise treatment efficacy, provided the overall protocol is followed.
Overdose
Accidental overdose of carmustine can result in severe, prolonged, and potentially fatal bone marrow suppression, along with acute organ toxicity affecting the liver, kidneys, and lungs. There is no specific antidote for carmustine overdose. Treatment is supportive and includes intensive monitoring of blood counts, administration of blood products (platelet and red cell transfusions) as needed, broad-spectrum antibiotics for neutropenic fever, and supportive care for organ dysfunction. Any suspected overdose must be reported immediately and managed in an intensive care or specialised oncology unit.
| Patient Group / Scenario | Dose Range | Schedule | Notes |
|---|---|---|---|
| Adults – single agent (previously untreated) | 150–200 mg/m² IV | Every 6 weeks | May be given as single dose or divided over 2 days |
| Adults – single agent (previously treated) | 100–130 mg/m² IV | Every 6 weeks | Reduced for prior chemotherapy or radiation |
| BEAM regimen (transplant conditioning) | 300 mg/m² IV | Single dose on day −6 | Transplant centres only; stem cell rescue required |
| Elderly (≥65 years) | Lower end of range | Every 6 weeks | Adjust for renal/hepatic function; enhanced monitoring |
| Renal impairment | Dose reduction required | Per oncologist | Monitor renal function closely; assess GFR before each cycle |
| Hepatic impairment | Dose reduction required | Per oncologist | Monitor liver function; may need treatment discontinuation |
Carmustine STADA powder must first be reconstituted with the provided sterile solvent (3 mL of absolute ethanol), then further diluted with 27 mL of sterile water for injection. The resulting solution is then diluted further in 500 mL of sodium chloride 0.9% or glucose 5% for intravenous infusion. The infusion should be administered over 1 to 2 hours. Faster infusion rates are associated with intense pain and burning at the infusion site and along the vein. Carmustine solution is light-sensitive and should be protected from direct light during preparation and infusion.
What Are the Side Effects of Carmustine STADA?
Carmustine causes significant side effects, reflecting its potent cytotoxic activity. The most important adverse effects are delayed bone marrow suppression (occurring 4 to 6 weeks after treatment), pulmonary toxicity, hepatotoxicity, and nephrotoxicity. Nausea and vomiting are very common within hours of infusion. All patients require close monitoring during and after each treatment cycle.
As a cytotoxic chemotherapy agent, carmustine affects both cancer cells and normal rapidly dividing cells, which accounts for many of its side effects. The bone marrow, gastrointestinal mucosa, hair follicles, and reproductive cells are particularly susceptible. The side effect profile of carmustine is well characterised from decades of clinical use, and modern supportive care measures (such as antiemetic medications, growth factors, and blood transfusions) can help manage many of these effects.
It is critically important to understand that carmustine's bone marrow suppression is characteristically delayed compared to most other chemotherapy drugs. While many cytotoxic agents cause their lowest blood counts (nadir) at 10 to 14 days after treatment, carmustine's myelosuppressive nadir typically occurs at 4 to 6 weeks. This delayed effect has implications for monitoring schedules and for planning subsequent treatment cycles. Furthermore, the myelosuppression caused by carmustine is cumulative, meaning that each successive dose may cause progressively more severe and prolonged cytopenias.
Pulmonary toxicity is another hallmark of carmustine therapy that sets it apart from many other chemotherapy agents. The risk of pulmonary fibrosis increases with cumulative dose, and cases have been reported even years after treatment completion. This late-onset lung damage can be irreversible and life-threatening, making long-term pulmonary follow-up essential for all patients who have received carmustine.
Very Common Side Effects
May affect more than 1 in 10 people
- Nausea and vomiting (occurs within 2 to 6 hours of infusion, lasting 4 to 6 hours)
- Delayed bone marrow suppression – thrombocytopenia (low platelets, nadir at 4–5 weeks)
- Delayed bone marrow suppression – leukopenia (low white cells, nadir at 5–6 weeks)
- Anaemia (low red blood cells)
- Pain and burning at the intravenous infusion site
- Facial flushing during infusion
Common Side Effects
May affect up to 1 in 10 people
- Pulmonary infiltrates and pulmonary fibrosis (dose-related, cumulative)
- Elevated liver enzymes (AST, ALT, alkaline phosphatase)
- Stomatitis (mouth sores and inflammation)
- Diarrhoea
- Alopecia (hair loss)
- Fatigue and malaise
- Hyperpigmentation of the skin (with prolonged exposure)
Uncommon Side Effects
May affect up to 1 in 100 people
- Nephrotoxicity (increased creatinine, decreased kidney size)
- Hepatic veno-occlusive disease (with high-dose regimens)
- Visual disturbances (optic neuritis, retinal haemorrhage)
- Encephalopathy (at high doses)
- Allergic or hypersensitivity reactions
- Secondary malignancies (acute leukaemia, myelodysplastic syndrome)
Rare Side Effects
May affect up to 1 in 1,000 people
- Severe tissue necrosis from extravasation
- Gynecomastia
- Chest pain
- Headache
- Tachycardia (rapid heart rate)
Contact your oncology team or emergency services immediately if you experience: unexplained bleeding, bruising, or petechiae (tiny red/purple spots); fever or signs of infection (especially during weeks 4 to 6 after treatment); persistent cough, shortness of breath, or difficulty breathing; severe or persistent nausea and vomiting that does not respond to prescribed antiemetics; signs of liver problems such as jaundice (yellowing of skin or eyes), dark urine, or abdominal pain; or any unusual or severe symptoms that concern you.
Your oncology team will provide detailed instructions about what to watch for and when to seek medical attention. Many of the side effects of carmustine can be managed effectively with supportive care, including antiemetic medications (such as ondansetron or granisetron given before and after the infusion), growth factors (such as G-CSF to support white blood cell recovery), and blood transfusions when necessary. Do not hesitate to contact your treatment centre if you have any concerns about your symptoms.
How Should You Store Carmustine STADA?
Carmustine STADA powder vials must be stored in a refrigerator at 2°C to 8°C, protected from light. The accompanying solvent is stored at room temperature below 25°C. As a cytotoxic agent, carmustine must be handled, stored, and disposed of according to institutional cytotoxic handling protocols.
Proper storage of carmustine is essential to maintain its chemical stability, potency, and safety. The powder for concentrate for solution for infusion must be kept refrigerated at a temperature between 2°C and 8°C (36°F to 46°F). The vials should be stored in their original carton to protect from light, as carmustine is light-sensitive and can degrade when exposed to direct light. The accompanying diluent (solvent) should be stored at room temperature, not exceeding 25°C (77°F).
Once reconstituted, the carmustine solution should be used within the timeframe specified in the product information, which is typically within 24 hours when stored at 2°C to 8°C or within 3 hours at room temperature (below 25°C). The reconstituted and diluted solution is light-sensitive and should be protected from light during storage and administration, for example by wrapping the infusion bag and giving set in light-protective covering.
Carmustine is a cytotoxic substance and must be handled with appropriate precautions at all times. Storage areas should be clearly labelled and access restricted to authorised personnel. Spill kits should be available in areas where carmustine is stored and handled. Any unused product or waste material must be disposed of in accordance with local requirements for cytotoxic waste. Carmustine should never be disposed of via regular household or healthcare waste streams.
Carmustine STADA is stored and handled exclusively by trained pharmacy and nursing staff within healthcare facilities. Patients do not store or handle this medication at home. If you have any questions about the preparation or administration of your chemotherapy, speak with your oncology pharmacist or nursing team. Do not use carmustine if the solution appears discoloured (an oily film forming on the surface of the reconstituted solution may indicate decomposition) or if there are visible particles.
What Does Carmustine STADA Contain?
Each vial of Carmustine STADA contains 100 mg of carmustine (BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea) as the active substance. The product also includes a solvent vial containing dehydrated ethanol for reconstitution. Carmustine has a molecular weight of 214.05 g/mol and the molecular formula C<sub>5</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>.
The active ingredient in Carmustine STADA is carmustine, a nitrosourea alkylating agent with the chemical name 1,3-bis(2-chloroethyl)-1-nitrosourea, commonly abbreviated as BCNU. Each vial contains 100 mg of carmustine as a yellow-orange lyophilised powder. The powder is supplied together with a vial of 3 mL of dehydrated (absolute) ethanol, which serves as the primary solvent for reconstitution.
Carmustine is a small, lipophilic molecule with a molecular weight of 214.05 daltons. Its lipophilic nature is responsible for its ability to cross the blood-brain barrier, a property that distinguishes it from many other chemotherapy agents and makes it particularly valuable for treating central nervous system tumors. After intravenous administration, carmustine undergoes rapid chemical decomposition in the body, forming reactive intermediates that alkylate DNA and other cellular macromolecules.
The reconstitution process involves first dissolving the carmustine powder in the 3 mL of dehydrated ethanol provided. The resulting ethanol solution is then further diluted with 27 mL of sterile water for injection, creating a concentrate containing approximately 3.3 mg/mL of carmustine. This concentrate is subsequently diluted in 500 mL of sodium chloride 0.9% or glucose 5% for intravenous infusion. The final diluted solution should be clear and free of particulate matter. Any oily film formation on the surface indicates chemical decomposition, and the solution should not be used.
The ethanol solvent used for reconstitution is an integral part of the product because carmustine has very limited solubility in aqueous solutions. The ethanol helps solubilise the drug and maintain its chemical stability during the initial reconstitution step. Healthcare professionals should be aware that the ethanol content in the reconstituted solution is clinically significant and should be taken into account when treating patients who cannot tolerate ethanol or when ethanol intake must be restricted.
Frequently Asked Questions About Carmustine STADA
Carmustine STADA is a chemotherapy medication used to treat several types of cancer. Its primary indications include malignant brain tumors (such as glioblastoma multiforme, brainstem glioma, medulloblastoma, and astrocytoma), Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. It is particularly valued for brain tumor treatment because it is one of the few chemotherapy drugs that can effectively cross the blood-brain barrier and reach cancer cells in the central nervous system. It is also a key component of the BEAM conditioning regimen used before autologous stem cell transplantation.
Carmustine STADA is given exclusively as a slow intravenous (IV) infusion in a hospital or specialised oncology setting. The powder is first reconstituted with the supplied ethanol solvent, then further diluted in an IV fluid bag (saline or glucose). The infusion is administered over 1 to 2 hours through a vein, usually in the arm or via a central venous catheter. Faster infusion rates can cause intense pain and burning at the injection site. You will never need to take carmustine at home – it is always administered by trained healthcare professionals.
Blood tests are critically important because carmustine causes delayed bone marrow suppression. Unlike many other chemotherapy drugs where blood counts recover within 2 to 3 weeks, carmustine's effects on blood cell production peak at 4 to 6 weeks after each dose. This means your platelet count (important for blood clotting) and white blood cell count (important for fighting infection) will be at their lowest several weeks after treatment. Weekly blood tests for at least 6 weeks after each dose allow your oncology team to monitor for dangerous drops in blood counts and intervene with supportive care (transfusions, growth factors, antibiotics) when needed.
Carmustine can cause pulmonary (lung) toxicity, including a condition called pulmonary fibrosis where scar tissue forms in the lungs. This risk increases with higher cumulative doses, particularly above 1,400 mg/m², but can occur at lower doses too. Pulmonary toxicity may develop during treatment or even years after treatment has ended. Symptoms include progressive shortness of breath, dry cough, and reduced exercise tolerance. Your oncologist will perform lung function tests before starting treatment and periodically during treatment to detect early signs of lung damage. If significant changes are found, treatment may need to be modified or stopped.
Yes, carmustine can affect fertility in both men and women. In men, it can reduce sperm production (oligospermia) or cause complete absence of sperm (azoospermia), which may be temporary or permanent. In women, it may cause ovarian failure and premature menopause. If you are of reproductive age and planning to have children in the future, discuss fertility preservation options with your oncologist before starting treatment. Options may include sperm banking for men or oocyte (egg) cryopreservation for women. Your healthcare team can refer you to a fertility specialist for counselling and procedures if appropriate.
Before each carmustine infusion, your oncology team will check your blood counts, liver function, and kidney function to ensure it is safe to proceed. You will typically receive pre-medications to help prevent nausea and vomiting, which are common during and after the infusion. Stay well hydrated before your appointment. Bring something to pass the time during the infusion (which lasts 1 to 2 hours), such as a book, music, or a tablet. Arrange transportation home, as you should not drive after receiving chemotherapy. Report any symptoms you have been experiencing since your last treatment to your nurse or oncologist before the infusion begins.
References and Sources
This article is based on internationally recognised medical and pharmaceutical guidelines. All information has been reviewed by qualified healthcare professionals and follows evidence-based principles.
- European Medicines Agency (EMA). Carmustine – Summary of Product Characteristics. EMA, 2024. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization, 2023.
- British National Formulary (BNF). Carmustine: Indications, Dose, Cautions, Side Effects. NICE, 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Carmustine (BiCNU) Prescribing Information. FDA, 2024. Available at: www.fda.gov
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 14th Edition, Chapter on Antineoplastic Agents – Alkylating Agents. McGraw-Hill Education, 2023.
- Stupp R, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005;352(10):987–996.
- Schmitz N, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet. 2002;359(9323):2065–2071.
- O'Driscoll BR, et al. BCNU pulmonary toxicity. Thorax. 1990;45(4):316–318.
- European Pharmacopoeia Commission. European Pharmacopoeia, 11th Edition. Council of Europe, 2023.
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, consisting of licensed physicians and specialists in clinical pharmacology and oncology with expertise in drug safety, pharmacovigilance, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology, oncology, and drug information. All content is researched and written using peer-reviewed sources, regulatory documents (EMA SmPC, FDA prescribing information), and international pharmaceutical guidelines.
iMedic Medical Review Board – independent panel of qualified physicians who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, and WHO standards. Oncology content receives additional specialist review.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.